Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LMDX save search
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
Published: 2023-06-20 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 30.46%
H: 17.17%
C: -2.98%
covid approval rsv
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 20.4%
H: 3.25%
C: -6.7%
covid test india approval covid-19
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
Published: 2023-02-06 (Crawled : 16:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 10.0%
H: 0.76%
C: -9.09%
fda covid solutions approval authorization molecular influenza
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 9.77%
H: 0.0%
C: -7.61%
conference financial results
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
Published: 2022-03-10 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 8.77%
H: 0.0%
C: -9.25%
report results
FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 8.54%
H: 3.01%
C: -7.67%
fda test molecular sars-cov-2
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
Published: 2022-10-12 (Crawled : 09:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 7.91%
H: 13.15%
C: 12.07%
care europe technology diagnostics innovation
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Published: 2023-07-31 (Crawled : 10:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 6.03%
H: 18.13%
C: -3.82%
distribution group care expansion commercial diagnostics agreement platform
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
Published: 2023-08-16 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 5.9%
H: 0.33%
C: -3.23%
conference financial results
LumiraDx Reports Second Quarter 2023 Results
Published: 2023-08-24 (Crawled : 12:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 4.83%
H: 2.33%
C: -7.02%
results
LumiraDx to Present at Raymond James Institutional Investors Conference
Published: 2023-03-03 (Crawled : 14:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 3.6%
H: 0.0%
C: -5.22%
conference
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
Published: 2022-06-08 (Crawled : 11:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 3.35%
H: 12.22%
C: 6.73%
star sars-cov-2
Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 2.97%
H: 3.74%
C: -2.67%
fda covid authorization test merge covid-19 emergency use authorization
LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 2.68%
H: 1.16%
C: -3.48%
financial results conference results
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
Published: 2023-03-14 (Crawled : 12:20) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 1.64%
H: 10.75%
C: 0.0%
conference year financial results
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Published: 2022-09-22 (Crawled : 09:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 1.59%
H: 0.0%
C: -8.59%
report rapid diagnostics in vitro
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 1.42%
H: 10.11%
C: -2.81%
test cardiovascular
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 1.01%
H: 5.0%
C: 0.0%
conference financial results
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
Published: 2022-05-26 (Crawled : 10:00) - prnewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.81%
H: 6.67%
C: 4.8%
care test growing diagnostic diabetes platform
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Published: 2021-12-23 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.77%
H: 3.92%
C: -2.18%
covid-19 ce mark covid test
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.